NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 96 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,123,240 | +9.8% | 1,984,336 | +165.8% | 0.23% | -53.3% |
Q2 2023 | $1,933,886 | -36.5% | 746,674 | 0.0% | 0.50% | -81.4% |
Q1 2023 | $3,046,430 | -18.7% | 746,674 | 0.0% | 2.67% | -23.8% |
Q4 2022 | $3,748,303 | -61.6% | 746,674 | 0.0% | 3.51% | -61.3% |
Q3 2022 | $9,766,000 | +2.0% | 746,674 | 0.0% | 9.07% | +11.4% |
Q2 2022 | $9,572,000 | -15.9% | 746,674 | 0.0% | 8.14% | +23.0% |
Q1 2022 | $11,387,000 | -13.9% | 746,674 | 0.0% | 6.62% | -12.0% |
Q4 2021 | $13,224,000 | -24.4% | 746,674 | -10.3% | 7.52% | -11.6% |
Q3 2021 | $17,494,000 | -40.6% | 832,274 | -44.3% | 8.50% | -11.0% |
Q2 2021 | $29,449,000 | -32.2% | 1,493,349 | 0.0% | 9.56% | -34.2% |
Q1 2021 | $43,412,000 | -31.2% | 1,493,349 | -28.3% | 14.52% | +8.7% |
Q4 2020 | $63,133,000 | – | 2,083,602 | – | 13.36% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |